Laroprovstat vs Lerodalcibep
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Laroprovstat
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)
Result source: NCT06173570
Lerodalcibep · Lerochol
Marketed by LIB Therapeutics and partners
NCT04797104 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.
Next expected readout: July 2028 · NCT07102511 (registry estimate)
Reported efficacy
Change from baseline compared to placebo in LDL-C level (24 weeks): LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) (met)
Result source: NCT04797104
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Laroprovstat | Lerodalcibep |
|---|---|---|
| LDL-C, % change | -46.6% vs 4.1%−50.7 vs placeboNCT061735707 other results
| -53% vs -45.3%avs inclisiranNCT050046751 other result
|
| Non-HDL-C, % change | -41.6% vs 3.5%−45.2 vs placeboNCT061735707 other results
| —Not posted · NCT04790513 |
| ApoB, % change | -37.0% vs 2.9%−39.9 vs placeboNCT061735707 other results
| —Not posted · NCT04790513 |
| Lp(a), % change | -19.4% vs 0%−19.4 vs placeboNCT061735703 other results
| —Not posted · NCT04790513 |
| 3-point MACE (% with event) | —Trial running · NCT06834932 | —Not posted · NCT04790513 |
LDL-C, % change
- Laroprovstat
- -46.6% vs 4.1%−50.7 vs placeboNCT06173570
7 other results
- -41.1% vs 4.1% NCT06173570
- -33.8% vs 4.1% NCT06173570
- -31.2% vs 4.1% NCT06173570
- -46.4% vs 3.4% NCT06173570
- -40.5% vs 3.4% NCT06173570
- -33.4% vs 3.4% NCT06173570
- -30.5% vs 3.4% NCT06173570
- Lerodalcibep
- -53% vs -45.3%avs inclisiranNCT05004675
1 other result
- -9.3% vs -11% NCT04034485
Non-HDL-C, % change
- Laroprovstat
- -41.6% vs 3.5%−45.2 vs placeboNCT06173570
7 other results
- -41.4% vs 2.9% NCT06173570
- -35.1% vs 3.5% NCT06173570
- -34.8% vs 2.9% NCT06173570
- -29.9% vs 3.5% NCT06173570
- -29.4% vs 2.9% NCT06173570
- -26.9% vs 3.5% NCT06173570
- -26.1% vs 2.9% NCT06173570
- Lerodalcibep
- —Not posted · NCT04790513
ApoB, % change
- Laroprovstat
- -37.0% vs 2.9%−39.9 vs placeboNCT06173570
7 other results
- -36.9% vs 2.4% NCT06173570
- -34.3% vs 2.9% NCT06173570
- -33.9% vs 2.4% NCT06173570
- -25.4% vs 2.9% NCT06173570
- -24.5% vs 2.4% NCT06173570
- -24.1% vs 2.9% NCT06173570
- -23.4% vs 2.4% NCT06173570
- Lerodalcibep
- —Not posted · NCT04790513
Lp(a), % change
- Laroprovstat
- -19.4% vs 0%−19.4 vs placeboNCT06173570
3 other results
- -19.6% vs 0% NCT06173570
- -11.2% vs 0% NCT06173570
- -7.5% vs 0% NCT06173570
- Lerodalcibep
- —Not posted · NCT04790513
3-point MACE (% with event)
- Laroprovstat
- —Trial running · NCT06834932
- Lerodalcibep
- —Not posted · NCT04790513
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Laroprovstat: 4 of 4 rows · Lerodalcibep: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Laroprovstat | Lerodalcibep |
|---|---|---|
| Dropout rate | 5.9%30 mga NCT06173570 · Phase 2 show 3 more results1.2%10 mg NCT06173570 · Phase 2 4.7%3 mg NCT06173570 · Phase 2 5.8%1 mg NCT06173570 · Phase 2 | 18.8%a NCT03847974 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.4%30 mga NCT06173570 · Phase 2 show 3 more results0%10 mg NCT06173570 · Phase 2 0%3 mg NCT06173570 · Phase 2 1.2%1 mg NCT06173570 · Phase 2 | 3.1%a NCT03847974 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.2%30 mga NCT06173570 · Phase 2 show 3 more results2.4%10 mg NCT06173570 · Phase 2 2.4%3 mg NCT06173570 · Phase 2 2.3%1 mg NCT06173570 · Phase 2 | 9.4%a NCT03847974 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 3 more results | a other adverse event 87.5% other (not including serious) adverse events were not monitored/assessed using specific adverse even 9.4% NCT03847974 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Laroprovstat
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
show 3 more results
Lerodalcibep
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Laroprovstat's landscape · Lerodalcibep's landscape